January 4, 2017 06:21 PM EST
R&D

Aeter­na Zen­taris dou­bles down on maci­more­lin PhI­II, and los­es

John Carroll

Editor & Founder

Two years af­ter the FDA hand­ed Aeter­na Zen­taris a sting­ing re­jec­tion for its pro­pos­al to mar­ket maci­more­lin for the eval­u­a­tion of growth hor­mone de­fi­cien­cy in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times